Research programme: virus-like particle vaccines - VBI Vaccines

Drug Profile

Research programme: virus-like particle vaccines - VBI Vaccines

Alternative Names: CMV eVLP - VBI; eVLP vaccines - VBI; GBM eVLP - VBI; Glioblastoma eVLP Vaccine - VBI Vaccines; Glioblastoma Immunotherapy; HCV eVLP - VBI; Prophylactic respiratory syncytial virus vaccine - VBI Vaccines; RSV vaccine - VBI Vaccines; VBI 1901; VLP-based Cytomegalovirus - VBI; Zika virus eVLP vaccine - VBI Vaccines; Zika virus vaccine - VBI Vaccines

Latest Information Update: 12 Oct 2016

Price : $50

At a glance

  • Originator Epixis; VBI Vaccines
  • Class Cancer vaccines; Virus-like particle vaccines
  • Mechanism of Action Cytomegalovirus protease inhibitors; Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cytomegalovirus infections; Hepatitis C; Medulloblastoma; Zika virus infection
  • Research Glioblastoma; Respiratory syncytial virus infections

Most Recent Events

  • 11 Oct 2016 VBI Vaccines announces intention to submit IND to US FDA in 1H-2017
  • 29 Aug 2016 Preclinical pharmacodynamics data released by VBI vaccines
  • 19 Jul 2016 Preclinical trials in Zika virus infection in USA (unspecified route) (Prevention)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top